Meningococcal Group AC Bivalent Conjugate Vaccine, Freeze Dried (MCV2) developed by Tianjin Cansino Biotechnology has been approved for clinical trial by China Food and Drug Administration (approval number: 2015L05221).

We received the clinical trial application acceptance notice in May, 2013 and submitted the materials to Center for Drug Evaluation (CDE) in December, 2013. MCV2 of Cansino is used for 3 months infants to 2 years old children, which can elicit memory immune responses for the prevention of epidemic cerebrospinal meningitis caused by Group A and C meningococcal.

Meningococcal meningitis is a life-threatening acute respiratory disease caused by Neisseria meningitidis (meningococcus). As a widespread invasive infection, it is associated with high mortality and drug resistance due to high mutation frequency of meningococca.